Business, energy, technology, markets and global industry news from Business News Today

rare neurology

PharmaDeviceNews rare neurology
Representative image of a pediatric therapy consultation, illustrating how Biogen’s salanersen breakthrough therapy designation could shape the next phase of spinal muscular atrophy treatment and rare neurology care.
Pharma & Biotech

Can salanersen help Biogen defend its rare neurology franchise beyond Spinraza?

Find out how Biogen’s salanersen could reshape spinal muscular atrophy treatment after FDA breakthrough therapy status.

Read More
Pharma & Biotech

Why Harmony Biosciences’ pitolisant approval changes the risk calculus in pediatric narcolepsy

FDA approval expands pitolisant into pediatric cataplexy. Explore what this changes for narcolepsy care, safety, and long-term strategy.

Read More